Ipamorelin
Ghrelin / GHSR pathway GH-release peptide
Overview
Ipamorelin is a five-residue pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, designed for sharp selectivity at the GHSR (ghrelin / growth-hormone secretagogue receptor). The structural feature that distinguishes it from the older and broader GHRP family (GHRP-2, GHRP-6, Hexarelin) is exactly that selectivity envelope: Ipamorelin engages GHSR while sparing the related receptors that drive cortisol, prolactin, and ACTH release. The absence of cortisol-axis activation is what makes the molecule the cleanest GH-selective option for routine 503A compounding workflows and for any research context where secondary-axis effects would contaminate the readout. For compounding pharmacy buyers, Vialdyne releases Ipamorelin acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The 5-residue sequence is straightforward by SPPS, so the standard batch packet centres on peak-integration RP-HPLC plus ESI-MS identity; LC-MS/MS sequence verification is available on request but is rarely the load-bearing test for a pentapeptide. Most catalogue volume is paired with a GHRH-class agonist (CJC-1295 no-DAC, Sermorelin, or Tesamorelin) in dual-pathway preparations. The canonical CJC-1295 + Ipamorelin pairing is supplied directly as a pre-blended co-lyophilised vial under the cjc-1295-ipamorelin SKU at the standard 5+5 mg fill, with non-standard ratios scoped under change-control. The companion [CJC-1295 + Ipamorelin pharmacology article](/insights/cjc-1295-ipamorelin-blend-pharmacology-guide) covers the dual-pathway rationale and the ratio considerations.
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
- CAS
- 170851-70-4
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 2 mg, 5 mg, 10 mg
- MOQ
- On request
- Lead time
- 7–14 days
- Storage
- -20°C, protect from light
Documentation available on request
- Certificate of Analysis (COA)
- HPLC Chromatogram
- Mass-spec identity (ESI-MS)
- Counter-ion (acetate vs TFA)
- Sterile-fill release pack (sterility, CCI, fill-weight)
- Bacterial endotoxin (LAL, USP <85>)
- Stability data on request
- SDS / MSDS
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Frequently asked questions
What makes Ipamorelin different from GHRP-2 and GHRP-6?▾
All three engage the GHSR (ghrelin receptor), but the off-target receptor coverage diverges. GHRP-2 and GHRP-6 also activate receptors that drive cortisol release and prolactin secretion, and GHRP-6 in particular activates appetite signalling, all of which become confounders in compounding-pharmacy applications and in cellular readouts. Ipamorelin's pentapeptide design specifically preserves GHSR binding affinity while losing the cortisol-pathway activation, making it the cleanest GHSR-selective agonist in routine 503A use. The trade-off is amplitude: GHRP-2 and GHRP-6 produce somewhat larger absolute GH-release magnitudes, while Ipamorelin produces a smaller but cleanly GH-selective pulse.
Why is Ipamorelin combined with CJC-1295 rather than used alone?▾
Two parallel pathways, additive output. Ipamorelin engages the GHSR; CJC-1295 engages the GHRH receptor. Both feed into the same somatotroph cells, and because the downstream signalling cascades reinforce rather than compete, the combined GH-release pulse runs materially larger than either component alone at matched individual doses. The standard combination ratio is 1:1 by mass, with 5+5 mg per vial as the typical fill. Bench work designed to isolate GHSR pharmacology is the right context for Ipamorelin used alone; for any 503A compounding workflow targeting GH-release amplitude, the dual-pathway combination is essentially universal.
What's the recommended reconstitution and aliquoting approach for Ipamorelin?▾
Reconstitute in bacteriostatic water for injection at standard concentrations (1-5 mg/mL is the typical working range). Solution stability at -20 C as single-use aliquots is reasonable, but as with the rest of the GH-axis class, freeze-thaw cycle count dominates measured-potency loss, slow temperature drift contributes much less. The operational rule is to sub-divide into the smallest workable single-use aliquots immediately after reconstitution and to cap cumulative thaw count at three or fewer per aliquot. The lyophilised vial itself rolls under the standard 24-month re-test window at -20 C, and the released-batch COA documents the re-test date for procurement planning.
Related peptides
Buyers who view Ipamorelin also ask about:
CJC-1295 (no DAC)
≥99.0%Modified GRF 1-29 · GHRH analog
- CAS
- 863288-34-0
- Vial
- 2 mg–10 mg
29-mer
Sermorelin
≥99.0%GHRH 1-29 fragment
- CAS
- 86168-78-7
- Vial
- 2 mg–10 mg
CJC-1295 + Ipamorelin
≥99.0%GH-axis blend (CJC-1295 no DAC + Ipamorelin)
- CAS
- —
- Vial
- 10 mg